Sertindole versus other atypical antipsychotics for schizophrenia
Referencias
Additional references
Altman DG, Bland JM. Detecing skewness from summary information. BMJ 1996;313:1200. [OLZ020600]
American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia, second edition. American Journal of Psychiatry. American Journal of Psychiatry, 2004:1‐114.
Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18:63‐101.
Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405‐11.
Carpenter WT, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681‐90.
Deeks J. Issues in the selection for meta‐analyses of binary data. Abstracts of 8th International Cochrane Colloquium; 2000 Oct 25‐28th; Cape Town, South Africa. 2000.
Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623‐9.
Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971‐80.
Duggan L, Fenton M, Rathbone J, Dardennes R, El‐Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD001359.pub2]
El‐Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD004578.pub3]
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7‐10.
Gaebel W, Falkai P, Weinmann S, Wobrock T. Treatment guidelines for schizophrenia [Behandlungsleitlinie Schizophrenie]. Steinkopf2006.
Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876‐83.
Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry 2006;163:185‐94.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5. The Cochrane Library2005; Vol. Issue 3.
Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on quality of life. Archives of General Psychiatry 2006;63:1079‐6.
Kane JM, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group. Clozapine for the treatment of treatment‐resistant schizophrenia: a double‐blind comparison with chlorpromazine. Archives of General Psychiatry 1988;45:789‐96. [MEDLINE: 1988325813]
Kane JM. Treatment programme and long term outcome in chronic schizophrenia. Acta Psychiatrica Scandinavica 1993;46:585‐93.
Kay SR, Opler LA, Fiszbein A. Positive and negative syndrome scale (PANSS) manual. North Tonawanda (NY): Multi‐Health Systems, 1986.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231‐8.
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366‐71.
Lewis R, Bagnall A‐M, Leitner M. Sertindole for schizophrenia (Review). Cochrane Database of Systematic Reviews 2005, Issue Issue 3. [Art. No.: CD001715]
Liebermann JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RSE, Davis SM. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353:1209‐23.
Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales ‐ a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;176:249‐52.
Möller HJ. New assessment of atypical antipsychotics [Aktuelle Bewertung neuer/atypischer Neuroleptika]. Nervenarzt 2000;71:329‐44.
Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799‐812.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408‐12.
Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii‐92. [MEDLINE: 10982317]
